M‐ VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant

Mark S. Soloway, Satoru Ishikawa, Tammy Taylor, Gilbert Ezell

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The cisplatin-based combination chemotherapy regimens of M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) or MVC (methotrexate, vincristine, cisplatin) were given to 25 patients with metastatic urothelial carcinoma, 13 with locally advanced bladder cancer, and 10 as adjuvant therapy after radical surgery. Toxicity was significant with two deaths. Forty-eight percent of the patients with metastatic disease had a complete (20%) or partial (28%) response. Survival was only improved if a CR was achieved. Nine of 13 patients given M-VAC/MVC as neoadjuvant therapy underwent cystectomy and six are free of disease (mean 31 months). Three of the four patients who did not have radical surgery are also free of disease. These regimens appear to be superior to cisplatin alone. In the overall response evaluation, however, toxicity is greater.

Original languageEnglish (US)
Pages (from-to)40-45
Number of pages6
JournalJournal of surgical oncology
Volume42
Issue number1 S
DOIs
StatePublished - 1989

Keywords

  • bladder cancer

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'M‐ VAC or MVC for the treatment of advanced transitional cell carcinoma: Metastatic, induction, and adjuvant'. Together they form a unique fingerprint.

  • Cite this